Johnson & Johnson announced today the U.S. Food and Drug Administration (FDA) approved DARZALEX FASPRO® (daratumumab and hyaluronidase-fihj) in combination with bortezomib, lenalidomide and ...
The combination of subcutaneous daratumumab with VRd was approved in July 2024 for induction and consolidation in patients ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results